Related references
Note: Only part of the references are listed.Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice
Alfred E. Chappell et al.
NUCLEIC ACIDS RESEARCH (2020)
The current state and future directions of RNAi-based therapeutics
Ryan L. Setten et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo
Annabelle Biscans et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index
Wen Shen et al.
NATURE BIOTECHNOLOGY (2019)
Evaluating the Impact of Variable Phosphorothioate Content in Tricyclo-DNA Antisense Oligonucleotides in a Duchenne Muscular Dystrophy Mouse Model
Lucia Echevarria et al.
NUCLEIC ACID THERAPEUTICS (2019)
Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2019)
Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways
Maire F. Osborn et al.
NUCLEIC ACIDS RESEARCH (2019)
Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo
Annabelle Biscans et al.
NUCLEIC ACIDS RESEARCH (2019)
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akin Akinc et al.
NATURE NANOTECHNOLOGY (2019)
Re-Engineering RNA Molecules into Therapeutic Agents
Martin Egli et al.
ACCOUNTS OF CHEMICAL RESEARCH (2019)
Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay
Hans J. Gaus et al.
NUCLEIC ACIDS RESEARCH (2019)
Advanced siRNA Designs Further Improve In Vivo Performance of GaINAc-siRNA Conjugates
Donald J. Foster et al.
MOLECULAR THERAPY (2018)
Reversal of siRNA - mediated gene silencing in vivo
Ivan Zlatev et al.
NATURE BIOTECHNOLOGY (2018)
Acute hepatotoxicity of 2′ fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins
Wen Shen et al.
NUCLEIC ACIDS RESEARCH (2018)
Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo
Matthew R. Hassler et al.
NUCLEIC ACIDS RESEARCH (2018)
Exploring PAZ/3′-overhang interaction to improve siRNA specificity. A combined experimental and modeling study
Adele Alagia et al.
CHEMICAL SCIENCE (2018)
Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver
Colton M. Miller et al.
NUCLEIC ACID THERAPEUTICS (2018)
Improving Small Interfering RNA Delivery In Vivo Through Lipid Conjugation
Maire F. Osborn et al.
NUCLEIC ACID THERAPEUTICS (2018)
RNAi modulation of placental sFLT1 for the treatment of preeclampsia
Anton A. Turanov et al.
NATURE BIOTECHNOLOGY (2018)
Targeted delivery of antisense oligonucleotides to pancreatic β-cells
C. Ammala et al.
SCIENCE ADVANCES (2018)
Visualization of self-delivering hydrophobically modified siRNA cellular internalization
Socheata Ly et al.
NUCLEIC ACIDS RESEARCH (2017)
Cellular uptake and trafficking of antisense oligonucleotides
Stanley T. Crooke et al.
NATURE BIOTECHNOLOGY (2017)
Overcoming cellular barriers for RNA therapeutics
Steven F. Dowdy
NATURE BIOTECHNOLOGY (2017)
Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases
Kathleen M. Schoch et al.
NEURON (2017)
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Kevin Fitzgerald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
5′-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo
Reka A. Haraszti et al.
NUCLEIC ACIDS RESEARCH (2017)
Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates
Jayaprakash K. Nair et al.
NUCLEIC ACIDS RESEARCH (2017)
Pharmacokinetic Profiling of Conjugated Therapeutic Oligonucleotides: A High-Throughput Method Based Upon Serial Blood Microsampling Coupled to Peptide Nucleic Acid Hybridization Assay
Bruno M. D. C. Godinho et al.
NUCLEIC ACID THERAPEUTICS (2017)
Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides
Shunsuke Wada et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Development of a Quantitative BRET Affinity Assay for Nucleic Acid-Protein Interactions
Timothy A. Vickers et al.
PLOS ONE (2016)
A High-Throughput Method for Direct Detection of Therapeutic Oligonucleotide-Induced Gene Silencing In Vivo
Andrew H. Coles et al.
NUCLEIC ACID THERAPEUTICS (2016)
Silencing Myostatin Using Cholesterol-conjugated siRNAs Induces Muscle Growth
Tayeba Khan et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2016)
siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes
Shigeo Matsuda et al.
ACS CHEMICAL BIOLOGY (2015)
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Richard S. Geary et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
Hepatocyte-Specific Delivery of siRNAs Conjugated to Novel Non-nucleosidic Trivalent N-Acetylgalactosamine Elicits Robust Gene Silencing in Vivo
Kallanthottathil G. Rajeev et al.
CHEMBIOCHEM (2015)
Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2015)
2′-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF
Wen Shen et al.
NUCLEIC ACIDS RESEARCH (2015)
Hydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse Brain
Julia F. Alterman et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2014)
Novel Hydrophobically Modified Asymmetric RNAi Compounds (sd-rxRNA) Demonstrate Robust Efficacy in the Eye
Michael Byrne et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2013)
Structural basis for 5′-nucleotide base-specific recognition of guide RNA by human AGO2
Filipp Frank et al.
NATURE (2010)
Antisense oligonucleotide pharmacokinetics and metabolism
Richard S. Geary
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Asymmetric Shorter-duplex siRNA Structures Trigger Efficient Gene Silencing With Reduced Nonspecific Effects
Chan Il Chang et al.
MOLECULAR THERAPY (2009)
Efficient in vivo delivery of siRNA to the liver by conjugation of α-tocopherol
Kazutaka Nishina et al.
MOLECULAR THERAPY (2008)
Asymmetric RNA duplexes mediate RNA interference in mammalian cells
Xiangao Sun et al.
NATURE BIOTECHNOLOGY (2008)
Chemical Modification of siRNAs for In Vivo Use
Mark A. Behlke
OLIGONUCLEOTIDES (2008)
Potent RNAi by short RNA triggers
Chia-Ying Chu et al.
RNA (2008)
Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner
Subba Rao Nallagatla et al.
RNA (2008)
Modified 27-nt dsRNAs with dramatically enhanced stability in serum and long-term RNAi activity
Takanori Kubo et al.
OLIGONUCLEOTIDES (2007)
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs
Christian Wolfrum et al.
NATURE BIOTECHNOLOGY (2007)
Position-specific chemical modification of siRNAs reduces off-target'' transcript silencing
Aimee L. Jackson et al.
RNA (2006)
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication
DV Morrissey et al.
HEPATOLOGY (2005)
Structural basis for 5′-end-specific recognition of guide RNA by the A-fulgidus Piwi protein
JB Ma et al.
NATURE (2005)
Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA
CR Allerson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Rational siRNA design for RNA interference
A Reynolds et al.
NATURE BIOTECHNOLOGY (2004)
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
J Soutschek et al.
NATURE (2004)
Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain
JB Ma et al.
NATURE (2004)
Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells
F Czauderna et al.
NUCLEIC ACIDS RESEARCH (2003)
Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing
J Harborth et al.
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2003)
Developments in RNA chemistry, a personal view
F Eckstein
BIOCHIMIE (2002)
RNA interference is mediated by 21-and 22-nucleotide RNAs
SM Elbashir et al.
GENES & DEVELOPMENT (2001)